“We are proud to support the ADAP Crisis Task Force and applaud their ongoing efforts in working with state and federal officials to secure the funding needed to appropriately meet this challenging public health need.” “Bristol-Myers Squibb has a longstanding commitment to HIV and AIDS,” said Raymond Sacchetti, senior vice president, U.S. “The Fair Pricing Coalition is pleased that Bristol-Myers Squibb continues to be a committed partner in meeting the needs of the HIV community.” “Ensuring access to treatment for HIV and AIDS requires the commitment and participation of government, industry and the community,” said Lynda Dee of AIDS Action Baltimore and member of the Fair Pricing Coalition.
Our long working relationship with Bristol-Myers Squibb made this agreement possible.” “We commend Bristol-Myers Squibb for responding to the unprecedented need faced by state ADAPs to provide access to HIV medicines and enhance our March agreement by providing additional support. “AIDS Drug Assistance Programs are a critical safety net to ensure people living with HIV/AIDS who have no other resources can continue to receive the HIV treatments they need,” said Dwayne Haught, spokesperson for the ADAP Crisis Task Force. Building on an agreement signed in March of 2010, today’s announcement marks a multi-year enhancement to assist ADAPs in meeting the challenges of increasing patient case loads and strained government funding.īristol-Myers Squibb has worked with the ACTF since its inception in 2002 to help ensure access to HIV medications, such as REYATAZ ® (atazanavir) and SUSTIVA ® (efavirenz). & WASHINGTON-( BUSINESS WIRE)- Bristol-Myers Squibb Company (NYSE: BMY) and the ADAP Crisis Task Force (ACTF) today announced an enhanced agreement to support the efforts of AIDS Drug Assistance Programs (ADAPs) to provide antiretroviral medicines to people living with HIV and AIDS. Additional support to ADAPs from Bristol-Myers Squibb added to March 2010 agreement
0 kommentar(er)
